The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer

G Middleton, L R Crack, S Popat, C Swanton, S J Hollingsworth, R Buller, I Walker, T H Carr, D Wherton, L J Billingham, G Middleton, L R Crack, S Popat, C Swanton, S J Hollingsworth, R Buller, I Walker, T H Carr, D Wherton, L J Billingham

Abstract

Background: The management of NSCLC has been transformed by stratified medicine. The National Lung Matrix Trial (NLMT) is a UK-wide study exploring the activity of rationally selected biomarker/targeted therapy combinations.

Patients and methods: The Cancer Research UK (CRUK) Stratified Medicine Programme 2 is undertaking the large volume national molecular pre-screening which integrates with the NLMT. At study initiation, there are eight drugs being used to target 18 molecular cohorts. The aim is to determine whether there is sufficient signal of activity in any drug-biomarker combination to warrant further investigation. A Bayesian adaptive design that gives a more realistic approach to decision making and flexibility to make conclusions without fixing the sample size was chosen. The screening platform is an adaptable 28-gene Nextera next-generation sequencing platform designed by Illumina, covering the range of molecular abnormalities being targeted. The adaptive design allows new biomarker-drug combination cohorts to be incorporated by substantial amendment. The pre-clinical justification for each biomarker-drug combination has been rigorously assessed creating molecular exclusion rules and a trumping strategy in patients harbouring concomitant actionable genetic abnormalities. Discrete routes of pathway activation or inactivation determined by cancer genome aberrations are treated as separate cohorts. Key translational analyses include the deep genomic analysis of pre- and post-treatment biopsies, the establishment of patient-derived xenograft models and longitudinal ctDNA collection, in order to define predictive biomarkers, mechanisms of resistance and early markers of response and relapse.

Conclusion: The SMP2 platform will provide large scale genetic screening to inform entry into the NLMT, a trial explicitly aimed at discovering novel actionable cohorts in NSCLC.

Clinical trial isrctn: 38344105.

Trial registration: ClinicalTrials.gov NCT02117167 NCT02154490.

Keywords: National Lung Matrix Trial; Umbrella Trial; adaptive trial design; non-small-cell lung cancer; stratified medicine.

© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology..

Figures

Figure 1.
Figure 1.
Key signalling pathways targeted in the National Lung Matrix Trial.
Figure 2.
Figure 2.
The CDKN2A–CDK4 axis.

References

    1. Lynch TJ, Bell DW, Sordella R et al. . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21): 2129–2139.
    1. Soda M, Choi YL, Enomoto M et al. . Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448(7153): 561–566.
    1. Kwak EL, Bang YJ, Camidge DR. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363(18): 1693–1703.
    1. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489(7417): 519–525.
    1. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511(7511): 543–550.
    1. Shaw AT, Ou SH, Bang YJ et al. . Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371: 1963–1971.
    1. Widemann BC, Marcus LJ, Fisher MJ et al. . Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). J Clin Oncol 2014; 32(5s suppl): abstr 10018.
    1. Scheffler M, Bos M, Gardizi M et al. . PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget 2015; 6(2): 1315–1326.
    1. Davies BR, Greenwood H, Dudley P et al. . Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumour activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012; 11(4): 873–887.
    1. Spoerke JM, O'Brien C, Huw L et al. . Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 2012; 18(24): 6771–6783.
    1. She QB, Halilovic E, Ye Q et al. . 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010; 18(1): 39–51.
    1. Ma L, Chen Z, Erdjument-Bromage H et al. . Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121(2): 179–193.
    1. Gavine PR, Mooney L, Kilgour E et al. . AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 72(8): 2045–2056.
    1. Paik PK, Shen R, Ferry D et al. . A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: preliminary antitumor activity and pharmacodynamic data. J Clin Oncol 2014; 32(5s suppl): abstr 8035.
    1. Liao RG, Jung J, Tchaicha J et al. . Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 2013; 73(16): 5195–5205.
    1. Guichard SM, Howard Z, Heathcote D et al. . AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer In Proceedings AACR 103rd Annual Meeting (Abstr 917), McCormick Place West 2012; 72.
    1. Pike KG, Malagu K, Hummersone MG et al. . Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 2013; 23(5): 1212–1216.
    1. Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 2009; 29(21): 5657–5670.
    1. Wagle N, Grabiner BC, Van Allen EM et al. . Brief report: response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014; 371: 1426–1433.
    1. Shaw RJ, Bardeesy N, Manning BD et al. . The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004; 6(1): 91–99.
    1. Gao Y, Xiao Q, Ma H et al. . LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci USA 2010; 107(44): 18892–7.
    1. Fry DW, Harvey PJ, Keller PR et al. . Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumour activity in human tumour xenografts. Mol Cancer Ther 2004; 3(11): 1427–1438.
    1. Konecny GE, Winterhoff B, Kolarova T et al. . Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res 2011; 17(6): 1591–1602.
    1. Puyol M, Martín A, Dubus P et al. . A synthetic lethal interaction between K-Ras oncogenes and CDK4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010; 18(1): 63–73.
    1. Ye X, Zerlanko B, Kennedy A et al. . Downregulation of Wnt signaling is an early signal for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell 2007; 27(2): 183–196.
    1. Kennedy AL, Morton JP, Manoharan I et al. . Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 2011; 42(1): 36–49.
    1. Camidge DR, Ou S-HI, Shapiro GI et al. . Efficacy and safety of crizotinib in patients with advanced MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 2014; 32(5s suppl): abstr 8001.
    1. Jänne PA, Yang JC, Kim DW et al. . AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372(18): 1689–1699.
    1. Jänne PA, Shaw AT, Pereira JR et al. . Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013; 14(1): 38–47.
    1. Ohashi K, Sequist LV, Arcila ME et al. . Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res 2011; 19(9): 2584–2591.
    1. Segal NH, Ou SH, Balmanoukian AS et al. . Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J Clin Oncol 2015; 33(suppl): abstr 3011.
    1. Thress KS, Paweletz CP, Felip E et al. . Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015; 216: 560–562.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren